Skip to main content
Equibles
NRXP logo

NRXP · NRX Pharmaceuticals, Inc. · Metrics

Track NRXP — free

Use NRXP with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research NRXP.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$2.49 +0.09 (+3.75%) At close · Oct 23
Rebalance outlook locked
Going-concern doubt — flagged Aug 14, 2026

Substantial doubt about the company's ability to continue as a going concern.

“the Company has concluded that substantial doubt exists about the Company's ability to continue as a going concern for a period of at least twelve months from the date of issuance of these consolidated financial statements.”
View the 10-Q filed Aug 14, 2026
Market Cap
$107.81M
Shares
43.30M
Volume · Oct 23 840.3K Avg daily vol (3M) 880.95K

NRXP metrics

64 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$2.49
Market cap
$107.81M

Price action

20 metrics
Price change (1W)
-4.2%
Price change (30D)
-17.8%
Price change (3M)
-33.6%
Price change (6M)
-15.3%
Price change (YTD)
-8.1%
Price change (1Y)
-22.2%
Trailing year
Price change (5Y)
—
52-week high
$4.62
52-week low
$1.68
Change from 52-week high
-46.1%
Change from 52-week low
+48.2%
Annualized volatility
85.6%
Annualized volatility (3M)
61.8%
Beta
2.0
RSI (14D)
32.0
Price vs SMA 50
-20.8%
Price vs SMA 200
-15.8%
Avg volume (3M)
880,804
Relative volume
0.9
Average dollar volume
$2.83M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
43.30M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
30.6×
reciprocal yield 3.3%
P / book
—
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-22.6%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-08-17

Profitability

9 metrics
Gross margin
46.6%
Operating margin
-586.2%
Trailing 12 months
Net margin
-691.8%
Gross profit (TTM)
$1.58M
Operating profit (TTM)
−$19.89M
Net income (TTM)
−$23.48M
Trailing 12 months
Diluted EPS (TTM)
—
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$-0.50

Growth

11 metrics
Revenue growth YoY
—
Year over year
Net income growth YoY
—
Revenue (TTM)
$3.39M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+33.2%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
—
Return on assets
-68.7%
Debt / equity
—
Current ratio
0.9
EBITDA (TTM)
−$19.70M
Free cash flow (TTM)
—
Quick ratio
0.9
Interest coverage
-17.4
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$26.69M
Total assets
$34.16M
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$19.77M
Capital expenditures (TTM)
$0
R&D (TTM)
$5.41M
SG&A (TTM)
$15.93M
Stock compensation (TTM)
$439,000
R&D / revenue
159.4%
Stock compensation / revenue
12.9%

Ownership (13F)

9 metrics
13F filers
48
13F filer change QoQ
+13
Institutional ownership
28.2%
Conviction holders (share of 13F filers)
2.1%
Crowding (high-turnover and private-fund holders)
8.1%
Private-fund adviser ownership
5.4%
Active holders' share change QoQ
+109.2%
Holder tenure
3.7
Price vs estimated holder cost
+46.9%

Ownership (registered funds)

1 metrics
Index-fund ownership
4.5%

Short interest

3 metrics
Short interest
22.6%
Latest settlement · 14.0 days to cover
Days to cover
14.0d
Short-squeeze score
72 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1719406 CUSIP 629444209 13F (30d) 3 filings 3 filers Visit website Investor relations